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ABSTRACT
Objective. Outcome assessment in 
large-vessel vasculitis (LVV) remains 
challenging and this impairs patient 
management and the conduct of clini-
cal studies. Previous proposals for out-
come tools have not included imaging. 
This study aimed to develop an imaging 
score to quantify damage in LVV and to 
assess the difference between Takayasu 
(TAK) and giant cell arteritis (GCA). 
Methods. Ninety-six patients (41 TAK, 
55 GCA) were identified from local 
registries at two University Hospitals 
in the UK. Radiologic lesions includ-
ing stenosis, occlusion and aneurysm 
were evaluated in 25 arterial regions 
by enhanced computed tomography or 
magnetic resonance angiography. Le-
sion correlation with combined dam-
age assessment scores was employed in 
a multiple regression analysis to define 
the weight of individual lesions and de-
velop a damage index.
Results. A numerical damage index 
was developed: the “Combined Arteri-
tis Damage Score (CARDS)”. The index 
was derived from a formula: number of 
regions with mild stenosis × 0.6 + num-
ber of regions with moderate to severe 
stenosis × 1.2 + number with occlu-
sions × 1.6 + number with aneurysms 
× 0.8 in 25 arterial regions. The median 
CARDS was higher in TAK than GCA 
(4.1 and 0.6, interquartile range 1.3–5.7 
and 0–3, p<0.001).
Conclusion. We have developed a dam-
age assessment tool, CARDS, based on 
imaging in LVV of potential value to 
clinical studies and patient manage-
ment. TAK and GCA differ in the radio-
logic severity of disease. 
Introduction
Takayasu arteritis (TAK) and giant cell 
arteritis (GCA) are subtypes of large-
vessel vasculitis (LVV). In the Chapel 
Hill Consensus Conference 2012, TAK 
and GCA were the only categories 
within the LVV classification and this 
was unchanged from the first, 1993 
Consensus statement (1, 2). The diag-
nosis of TAK is often delayed since 
TAK patients may be asymptomatic 
or have non-specific symptoms, such 
as, fever, fatigue, and myalgia. When 
specific symptoms, such as, pulse loss, 
claudication, bruits, and blood pres-
sure discrepancy appear, the patient 
will already be in an advanced stage 
(3). GCA typically has a more acute 
symptomatic presentation with tempo-
ral arteritis (4, 5), thus the time from 
symptom to diagnosis is longer in TAK 
than GCA (median 21.4 month and 2.7 
months, respectively, p=0.05) (6). It is 
important to make the diagnosis early 
to allow the opportunity for treatment 
in order to minimise the development 
of irreversible damage. This is of par-
ticular importance in TAK patients of 
young age and has been standardised 
in consensus guidelines (7, 8). More 
recently, biologics, such as, rituximab, 
anti-TNF antibody therapies and tocili-
zumab have been used for patients with 
refractory disease (9, 10), but the evi-
dence supporting these modalities in 
TAK is weak, in part due to an absence 
of reliable outcome measures (11-13). 
In GCA clinical trials, C-reactive pro-
tein (CRP), erythrocyte sedimentation 
rate (ESR) levels and characteristic 
symptoms have been used as outcome 
measures although their validation has 
been limited (14-16).
The development of outcome meas-
ures have facilitated clinical trials in 
ANCA-associated vasculitis with di-
rect impacts on patient benefit. The 
Birmingham Vasculitis Activity Score 
(BVAS) (17) and Vasculitis Damage 
Index (VDI) (18) were originally de-
veloped to assess vasculitic activity and 
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the accrual of all cause damage in any 
vasculitic syndrome including LVV. 
Although validated in small-vessel 
vasculitis they have proved less useful 
in LVV studies (13). In part, this has 
been due to the narrow range of items 
attributable to LVV in BVAS and VDI 
and in addition there has been difficulty 
in discriminating whether a clinical or 
radiologic feature results from active 
disease or irreversible damage. The 
combined damage assessment (CDA) 
was developed as a more extended sys-
tem for damage assessment than the 
VDI (19).
In contrast to small-vessel vasculitis, 
the visualisation of vascular pathology 
by imaging in LVV has the potential to 
provide information on both activity 
and damage. Disease activity may be 
reflected by wall thickness or oedema 
detected by magnetic resonance imag-
ing or angiography (MRI/MRA), en-
hanced CT, ultrasound (US) and with 
18F-fluorodeoxyglucose (FDG) uptake 
detected by positron emission tomog-
raphy (PET). In the advanced stage, 
damage is assessed by stenosis, occlu-
sion, aneurysm or dilatation which are 
irreversible lesions detected by MRI, 
enhanced CT, US and angiography 
(13, 20, 21). Current assessment tools 
in TAK employ clinical and laboratory 
variables but not imaging and have had 
limited usefulness (22, 23). This study 
aimed to develop an imaging damage 
score in LVV by determining the opti-
mised weight of imaging findings and 
to assess the difference between TAK 
and GCA and the correlation between 




96 sequential patients with LVV and 
disease below the head and neck at-
tending the vasculitis clinic at Ad-
denbrooke’s Hospital, Cambridge and 
Botnar Research Centre, Oxford were 
identified by retrospective chart re-
view. These patients all had imaging 
abnormalities defined as arterial wall 
thickness, stenosis, occlusion or aneu-
rysm/dilation by enhanced CT or MRI/
MRA, and defined as FDG uptake by 
PET/CT once. All patients met Chap-
el Hill 2012 Consensus definitions of 
LVV (1). TAK was defined as having 
arterial lesions of the aorta and/or pri-
mary branch vessels attributed to vas-
culitis and younger than 40 years at 
disease onset (6, 24). GCA was defined 
as having arterial lesions of the aorta 
and/or primary branch vessels attribut-
ed to vasculitis and older than 50 years 
at disease onset. In accordance with 
current UK ethical guidelines, ethical 
approval was not required because this 
work includes only retrospective data 
collected during routine clinical care or 
audit.
Data elements
Age at disease onset, age at diagno-
sis, sex, clinical symptoms at diagno-
sis, CRP, and ESR levels at diagnosis, 
use of oral glucocorticoids (converted 
to the equivalent prednisolone dose), 
immunosuppressant and, biologic ex-
posure and cumulative glucocorticoid 
dose were assessed retrospectively. 
There is no established gold standard 
for damage assessment in TAK. There-
fore CDA scores were used to deter-
mine the ‘weight’ of lesions defined by 
imaging (25). CDA was chosen because 
it includes more items than VDI, 135 
items in 17 categories and is potential-
ly more sensitive. Recent large-scale 
clinical trials in small-vessel vasculi-
tis are employing the CDA (26). CDA 
was measured on the date when imag-
ing was performed. At the same time, 
physician global assessment (PGA) of 
damage using a 10-point Likert scale 
was also measured (26). 
Imaging
For the imaging definitions of lesions 
and their distribution subjects were se-
lected with reference to cohorts from 
the USA, Italy, China and Japan (the 
total number of patients was 762) (27-
30). Namely, wall thickness, stenosis, 
occlusion and aneurysm (including di-
lation). We employed enhanced CT or 
MRA with images from the neck to the 
abdomen (20, 31). Furthermore, steno-
sis was sub-classified as mild, <50% 
or moderate to severe, 50-99% nar-
rowing. The following arterial regions 
were evaluated in 25 subjects; carotid 
artery, vertebral artery, brachiocephalic 
artery, subclavian artery, axillary ar-
tery, ascending aorta, aortic arch, de-
scending aorta, abdominal aorta, celiac 
artery, superior mesenteric artery, renal 
artery, iliac artery, pulmonary artery 
bilaterally and coronary artery includ-
ing right coronary artery, left anterior 
descending coronary artery, left cir-
cumflex coronary artery and left main 
trunk. All images were reviewed by a 
vascular radiologist and a rheumatolo-
gist trained in vascular radiology. Im-
aging review was blinded with regard 
to the clinical features. Coronary artery 
lesions were included if detected on 
coronary angiography performed for 
symptomatic reasons.
Surgical interventions including an-
gioplasty, stent, bypass surgery, heart 
valve replacement, heart transplant and 
pneumonectomy were evaluated. The 
procedure was counted twice when the 
patient had a second intervention with-
in the same arterial region. In a subset 
of patients, quality of life (QOL) data 
was available: EuroQol five dimension 
(EQ-5D) (32), short-form 36 health 
status questionnaire (SF-36) (33) and 
patient visual analogue scale (PTVAS) 
(26, 34). 
Statistical analysis
Statistical analysis was performed us-
ing SPSS software, v. 22.0J (IBM Ja-
pan). Normally distributed continuous 
data were summarised with means and 
either SDs or 95% confidence intervals 
(95% CIs) and were analysed using 
parametric tests (Student’s t-test) and 
Pearson correlation coefficient. Non-
normally distributed data were sum-
marised with medians and interquartile 
range (IQR) and were analysed using 
non-parametric tests (Mann-Whitney 
U-test) and Spearman’s correlation 
coefficient. Categorical data were sum-
marised with percentages and were 
analysed using a chi-square test or, 
Fisher’s exact test. A multiple regres-
sion analysis was constructed using a 
forced entry method and a step-wise 
method. Intra- and inter-observer reli-
ability of imaging scores were evalu-
ated by calculating intraclass corre-
lation coefficients. Unless otherwise 
specified, p-values less than 0.05 were 
considered significant.
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Results
Total patient damage and imaging 
findings
96 patients (74 female, 77%) with 
LVV were evaluated. The median 
CDA score was 6 (IQR 2–9). In the 
distribution of organ systems involved 
in the CDA, vascular disease was the 
most frequent, present in 67 patients 
(69.8%), followed by cardiac (60.4%), 
then ‘other’ (41.7%). The category of 
‘others’ included surgical intervention 
and side effects of medication. There 
were no patients with damage of the 
nose, sinuses or subglottis. 58 patients 
(60.4%) were evaluated by enhanced 
CT and 38 (39.6%) by MRA. 
Stenosis was the most frequent lesion, 
present in 65.6% of patients: ’mild’ 
in 36.5% and ‘moderate to severe’ in 
52.1%. Other lesions were wall thick-
ness (42.7%), occlusion (26%), and an-
eurysm (14.6%). Stenosis was distrib-
uted the most widely in 23 of 25 arterial 
regions (92%), followed by wall thick-
ness in 17 of 25 (68%), occlusion in 16 
of 25 (64%) and aneurysm in 12 of 25 
(48%). The most frequently involved 
arterial region was the left subclavian 
artery in 35% patients, followed by the 
descending aorta (33%), aortic arch 
(29%) and left carotid artery (28%).
Weight of imaging findings
Multiple regression analysis was per-
formed with a forced entry method 
to determine the optimised weight of 
imaging findings. CDA was set as an 
independent variable, and the total 
number of lesions with stenosis, occlu-
sion or aneurysm in 25 arterial regions 
as the dependent variables. The lesions 
before surgical intervention were car-
ried over to reflect cumulative damage. 
If the patient had had a surgical inter-
vention, the corresponding lesion prior 
to surgical intervention was scored.
As a result, a regression model was 
achieved, the Equation representing 
CDA and weights of imaging findings 
were as follows; CDA = 3.271 + mild 
stenosis - 0.646, moderate and severe 
stenosis - 1.202, occlusion - 1.555, and 
aneurysm - 0.830 (Table I). These re-
gression coefficients were simplified 
and employed as the lesion weighting. 
The number and weight of lesions in 
each region derived a damage index: 
the “Combined Arteritis Damage Score 
(CARDS)” with CARDS = number of 
mild stenosis × 0.6 + number of mod-
erate to severe stenosis × 1.2 + num-
ber of occlusions × 1.6 + number of 
aneurysms × 0.8. The maximum value 
is 40 if all 25 arterial regions have oc-
clusions. The median CARDS in the 
combined TAK/GCA population was 
1.7 (IQR 0 to 4.75). The inter-observer 
reliability using the intra-class correla-
tion coefficients in 30 patients selected 
randomly was 0.92 (95% CI 0.835 to 
0.961) between a vascular radiologist 
and a rheumatologist. The intra-ob-
server reliability assessed by a radiolo-
gist was 0.94 (95% CI 0.829 to 0.978) 
in 15 patients and by a rheumatolo-
gist was 0.91 (95% CI 0.765 to 0.969) 
(Supplemental Table I). 
Comparison between TAK and GCA 
for validation
• Patient characteristics
Forty-one TAK patients and 55 GCA 
patients were studied (Supplemental 
Table II). Mean age at onset in TAK 
was 29.5 years and GCA was 64.7 
years (p<0.001). The delay from symp-
tom onset to diagnosis was longer in 
TAK than GCA (median 31.5 months 
and 3 months, respectively p<0.001). 
Median disease duration was longer in 
TAK than GCA (median 100.4 months 
and 36.5 months, p<0.001). Median 
CRP and ESR level at diagnosis was 
higher in GCA than TAK (median 
CRP 81 mg/l and 30 mg/l, p<0.001, 
median ESR 96 mm/h and 34.5 mm/h, 
p<0.001). At the time of recent assess-
ment these levels were typically low 
or normal and not different between 
Table I. Weight of imaging by multiple regression analysis.
 Regression p                  95% confidence interval
 coefficient 
Intercept 3.271 <0.001 2.330 4.213
Stenosis mild(<50%) 0.646 0.041 0.028 1.284
Stenosis moderate to severe(>50%) 1.202 <0.001 0.755 1.849
Occlusion 1.555 0.001 0.678 2.432
Aneurysm 0.830 0.029 0.085 1.574
A multiple regression analysis was constructed using a forced entry method. P values less than 0.05 
were considered significant.
The regression coefficients were simplified and employed as weight of lesions. We defined the number 
and weight of lesions in each artery as a damage index and propose the name: “Combined Arteritis 
Damage Score (CARDS)’; 
CARDS= number of mild stenosis × 0.6 + number of moderate and severe stenosis × 1.2 + number of 
occlusions × 1.6 + number of aneurysms × 0.8.
Table II. Assessment for damage and quality of life in patients with Takayasu arteritis and 
giant cell arteritis.
 TAK, n=41 GCA, n=55 p-value
CDA, mean (SD) 7.4 (3.8) 5 (4.0) 0.005
PGA, median (IQR) 5 (4-7) 2 (1-5) <0.001
 TAK, n=16 GCA, n=15
 
SF-36 (Physical component summary), 31.2 (9.5) 35 (10.9) 0.198 
   mean (SD) 
SF-36 (Mental component summary),  42.8 (9.6) 52.4 (7.3) 0.004
   mean (SD) 
PTVAS, mean (SD) 51.7 (30) 64 (18) 0.04
EQ5D, median (IQR) 0.655 (0.542-0.752) 0.796 (0.62-0.796) 0.119
Normally distributed continuous data were summarised with means and SD and were analysed using 
parametric tests (Student’s t-test). Non-normally distributed data were summarised with medians and 
interquartile ranges and were analysed using non-parametric tests (Mann-Whitney U-test). p-values 
less than 0.05 were considered significant.
CDA: combined damage assessment; PGA: physician global assessment of damage; SF-36: short-form 
36 health status questionnaire; PTVAS: patient visual analogue scale; EQ5D: Euro quality of life-5 
dimensions.
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TAK and GCA (Supplementary Table 
II). Some patients did not satisfy ACR 
classification criteria since we defined 
TAK as younger than 40 years and 
GCA as older than 50 years at disease 
onset having arterial lesions of the aor-
ta and/or primary branch vessels attrib-
uted to vasculitis. The patient treatment 
histories are described in Supplemental 
Table III.
• Damage
Median CDA was higher in TAK than 
GCA (median 7 and 4, p=0.003) (Ta-
ble II) reflected by higher frequencies 
of ‘vascular’ and ‘other’ CDA items in 
TAK than in GCA. The frequency of 
ocular damage was higher in GCA than 
in TAK (Fig. 1). Median PGA for dam-
age was also higher in TAK than GCA 
(median 5 and 2, p<0.001). 
• Quality of life
QOL was assessed in a subgroup of 
clinic patients: TAK 16, GCA 15. TAK 
patients had worse scores than GCA 
for the Mental component summary of 
SF36 (mean 42.8 and 52.4, p=0.004), 
and for PTVAS (mean 51.7 and 64, 
p=0.04). There was a trend for the 
Physical component summary of SF36 
to be lower in TAK than in GCA (mean 
31.2 and 35, p=0.198) (Table II).
• Imaging findings
Moderate to severe stenoses, occlu-
sions and aneurysms were more com-
monly seen in TAK than in GCA (Fig. 
2a, 2b). The most frequently involved 
arterial region in 25 vessels in TAK 
was the aortic arch in 39% of patients 
with increased wall thickness, the ce-
liac artery in 31% of patients with sten-
oses, the left subclavian and superior 
mesenteric artery in 10% of patients 
with occlusions, the ascending aorta 
in 22% of patients with aneurysms, the 
left renal artery in 15% of patients hav-
ing had surgical interventions. (Sup-
plemental Fig. 1). The most frequently 
involved arterial region in 25 vessels 
in GCA was the descending aorta in 
29% of patients with increased wall 
thickness, the left subclavian artery in 
26% of patients with stenosis, the right 
subclavian and axillary artery in 5% of 
patients with occlusion, the ascending 
aorta in 5% of patients with aneurysm. 
(Supplemental Fig. 2).
• Combined Arteritis Damage Score 
(CARDS)
The number of lesions in 25 vessels 
was counted and multiplied by the 
weighting as follows; number of mild 
stenoses × 0.6 + number of moderate to 
severe stenoses × 1.2 + number of oc-
clusions × 1.6 + number of aneurysms 
× 0.8. As a result, the median CARDS 
was higher in TAK than GCA (4.1 and 
0.6, p<0.001) (Table IIIa). Moreover, 
it was possible to identify three vari-
ables as predictors of a higher CARDS 
in TAK with multiple regression anal-
ysis with a step-wise method (Table 
IIIb). The use of biologic agents and 
constitutional symptoms at diagnosis 
were predictors for a lower CARDS. 
The disease duration was a predictor 
Fig. 1. Spread of organ systems involved in the CDA between Takayasu arteritis and giant cell arte-
ritis.
Items of CDA were compared between Takayasu arteritis and Giant cell arteritis. Combined damage 
assessment (CDA) includes more items than VDI, 135 items in 17 categories. The category of ‘others’ 
included surgical intervention and side effects of medication.
Categorical data were summarised with percentages and were analysed using a chi-square test, Fisher’s 
exact test. p-values less than 0.05 were considered significant.
Fig. 2. Frequency of each lesion between Takayasu arteritis and Giant cell arteriti.
2a. Frequency of wall thickness, stenosis, occlusion and aneurysm were compared between Takayasu 
arteritis and Giant cell arteritis.
2b. Stenosis was classified into two stages. Mild stenosis was defined as <50%, moderate to severe ste-
nosis as 75-99%.The following arterial regions were evaluated in 25 subjects; carotid artery, vertebral 
artery, brachiocephalic artery, subclavian artery, axillary artery, ascending aorta, aortic arch, descend-
ing aorta, abdominal aorta, celiac artery, superior mesenteric artery, renal artery, iliac artery, pulmonary 
artery bilaterally and coronary artery including right coronary artery, left anterior descending coronary 
artery, left circumflex coronary artery and left main trunk.
Categorical data were summarised with percentages and were analysed using a chi-square test, Fisher’s 
exact test. p-values less than 0.05 were considered significant.
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for a higher CARDS. In a single corre-
lation study for TAK, CARDS did not 
correlate with CRP or ESR at assess-
ment, disease duration or onset age. 
In the subset studied, QOL tools did 
not correlate with CARDS or CDA. In 
GCA, there were no associations with 
multiple regression analysis. In a single 
correlation study, CARDS was higher 
in younger patients. CARDS correlated 
with the number of surgical interven-
tions positively. CARDS did not cor-
relate with CRP, ESR at assessment. 
CDA was positively correlated with 
the physical component score of SF36 
and PTVAS.
Discussion
Outcome assessment in LVV remains 
challenging and this impairs patient 
management and the conduct of clini-
cal studies. Previous proposals for out-
come tools have not included imaging, 
so an attempt has been made to stand-
ardise and quantify image assessment 
in LVV by the development of an im-
aging damage score, CARDS, and to 
compare the results between TAK and 
GCA patients. 
Wall thickness was excluded from 
CARDS because it was not possible to 
compose multiple regression equations 
with wall thickness and it is controver-
sial whether wall thickness represents 
activity or damage. Tso et al. compared 
vessel wall oedema with disease activ-
ity in 24 TAK patients: MRA revealed 
vessel wall oedema in 94% of active 
disease patients, and in 56% of those 
in clinical remission (35). Arnaud et al. 
compared MRI findings to PET scan 
with semi-quantitative assessment of 
FDG uptake graded 0-3 in 28 TAK pa-
tients (36). There were no associations 
between the semi-quantitative assess-
ment of FDG uptake and the presence 
of vascular wall thickening and gado-
linium uptake. Occasionally, it is diffi-
cult to distinguish wall thickness from 
artefact but this manifestation requires 
further study. 
We carried over the lesions before sur-
gical intervention, giving one point in 
CARDS, because we wanted to reflect 
the cumulative vascular damage and 
to distinguish between patients who 
improved by intervention and patients 
with fewer lesions from disease onset. 
Additionally, stenosis was classified 
into two stages of severity in CARDS. 
This simplified evaluation, but it may 
also be useful to subdivide stenosis 
more strictly when we assess longitudi-
nal change. In this study, the subgroup, 
‘aneurysm’, was not subdivided by an-
giographic severity because it was dif-
ficult to determine severity subgroups 
although it was possible to measure the 
size of aneurysms. 
In the inter-observer reliability, the cor-
relation coefficient was high between a 
radiologist and rheumatologist which 
supports the general use of CARDS not 
only by radiologists but also by suit-
ably trained rheumatologists. 
Because there is considerable evidence 
of angiographic differences between 
TAK and GCA, an internal validation 
was performed by comparing CARDS 
between syndromes. This required us-
ing age of onset to assist in diagnostic 
categorisation because asymptomatic 
TAK patients in the early stage did not 
fulfill ACR criteria although they had 
characteristic arterial lesions. Previous 
reports have described phenotypic dif-
ferences in addition to the noted age 
disparity with TAK below and GCA 
above 50 years of age by latent class 
analysis (6). CARDS was higher in 
TAK than in GCA. Our results clarified 
that there are differences in severity, 
although similarities in the pathology 
and distribution of vascular lesions 
have led to claims that TAK and GCA 
are one disease (37, 38). One reason for 
this difference may relate to the delay 
from onset to diagnosis, which is long-
er in TAK than in GCA. Some TAK 
patients are often in an advanced stage 
before diagnosis. This may be reflected 
by the lower CRP and ESR at diagnosis 
in TAK since activity of some patients 
has already subsided.
The use of biologic agents and con-
stitutional symptom at diagnosis were 
identified as predictors for a lower 
CARDS and this requires confirma-
tion. If the patients have constitutional 
symptoms, they will be diagnosed and 
treated earlier with the potential to re-
duce irreversible damage. This needs 
further verification although there is 
a possibility that use of biologics de-
creases irreversible damage. CARDS 
did not correlate with CRP and ESR at 
assessment in TAK and GCA, unsur-
prisingly, because CARDS is intended 
as a measure of damage but not activity. 
CARDS was higher in younger patients 
than older patients at age of onset of 
GCA. Schmidt et al. described patients 
with large-vessel lesions in GCA were 
younger than those with classic tempo-
ral arteritis (39). It is possible that GCA 
patients with temporal arteritis reduce 
irreversible damage since they are di-
Table III. Comparison and assessment for damage with CARDS between Takayasu arteri-
tis and giant cell arteritis.
IIIa
 TAK, n=41 GCA, n=55 p-value
CARDS, median (IQR) 4.1 (1.3-5.7) 0.6 (0-3) <0.001
Non-normally distributed data were summarised with medians and interquartile ranges and were ana-
lysed using non-parametric tests (Mann-Whitney U-test). p-values less than 0.05 were considered sig-
nificant.
CARDS, Combined Arteritis Damage Score; 
IIIb
Log10 CARDS Regression p 95% confidence interval
 coefficient 
Intercept 0.684 p<0.001 0.472 0.895
Disease duration 0.002 0.001 0.001 0.004
Constitutional symptom at diagnosis -0.402 0.001 -0.630 -0.173
Use of biologics -0.227 0.033 -0.434 -0.020
A multiple regression analysis was constructed using a step-wise method. p-values less than 0.05 were 
considered significant.
CARDS: Combined Arteritis Damage Score.
Log10 CARDS: The variable CARDS was logarithmically transformed.
S-144 Clinical and Experimental Rheumatology 2017
A score for assessment in large-vessel vasculitis / D. Nakagomi et al.
agnosed and treated at an early stage.
In contrast to small-vessel vasculitis 
the visualisation of vascular pathology 
by imaging provides a major oppor-
tunity in LVV. The imaging diagnosis 
remains the gold standard since lesions 
visualised by the imaging represent the 
activity or damage in LVV directly. It 
is unclear whether PET is sufficiently 
sensitive to become the gold standard 
for activity assessment in LVV and car-
ries high radiation exposure (36, 40). 
In specific activity measures of TAK, 
three tools have been described (22, 
23, 41). On the other hand, in specific 
damage measures, only the Takayasu 
Arteritis Damage Score has been re-
ported (42). This outcome measure also 
evolved from DEI.TAK and does not 
include imaging assessment. There-
fore, outcome measures are needed to 
include not only physical findings but 
also imaging. The benefits of CARDS 
are that a patient can be evaluated in a 
short time and longitudinal changes as-
sessed or compared with other patients 
in a semi-quantitative manner. CARDS 
has the potential to represent not only 
the results of radiologic imaging but 
also indirectly all cause damage be-
cause it is derived from an association 
between imaging and the CDA.
This study had some limitations. It was 
a two centre retrospective study with a 
small sample size that reduces statisti-
cal power and may be influenced by 
referral bias. Another limitation is that 
both CT and MRI were included for 
imaging assessment. Efficacy of both 
modalities in LVV has already been 
established (20,31), and their features 
such as spatial resolution are different, 
which might influence the radiological 
results, but there were no significant 
differences in the CARDS between 
CT and MRI (Supplemental Table IV). 
Further validation with replication in 
another cohort, change over time, and 
correlation with longer term outcomes 
to establish CARDS will be needed.
Conclusions
In conclusion, a key goal of treatment 
of LVV is the control of disease activ-
ity in order to prevent the accrual of 
disease related damage. Especially, 
there are no clinical trials with large 
numbers although it has been reported 
biologics are useful in TAK in some 
case reports recently. Without reliable 
assessment tools it will be difficult to 
introduce newer agents. A damage as-
sessment tool based on imaging has 
been developed in LVV and this should 
be potential of value to clinical studies 
and patient management.
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